Fig. 4.

Relapse risk and relapse-free survival curves illustrate that regardless of the timing of minimal residual disease (MRD) detection, once found it persists as a prognostic factor regardless of whether it later is negative (This research was originally published in Blood [8]). Residual disease (RD) groups: RD positive–MRD detected at end of therapy. NO RD–MRD not detected at end of induction, during therapy, nor at end of therapy. RD negative but previously positive—Negative at the end of therapy but among the regimen-specified monitoring points during therapy, there was at least one positive MRD finding.